>
Switch to:

PTC Therapeutics Long-Term Capital Lease Obligation

: $91.1 Mil (As of Mar. 2022)
View and export this data going back to 2013. Start your Free Trial

PTC Therapeutics's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2022 was $91.1 Mil.

PTC Therapeutics's quarterly Long-Term Capital Lease Obligation declined from Sep. 2021 ($94.9 Mil) to Dec. 2021 ($93.7 Mil) and declined from Dec. 2021 ($93.7 Mil) to Mar. 2022 ($91.1 Mil).

PTC Therapeutics's annual Long-Term Capital Lease Obligation increased from Dec. 2019 ($9.0 Mil) to Dec. 2020 ($102.6 Mil) but then declined from Dec. 2020 ($102.6 Mil) to Dec. 2021 ($93.7 Mil).

PTC Therapeutics Long-Term Capital Lease Obligation Historical Data

The historical data trend for PTC Therapeutics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PTC Therapeutics Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Long-Term Capital Lease Obligation
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 9.02 102.55 93.67

PTC Therapeutics Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Long-Term Capital Lease Obligation Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 97.92 96.48 94.88 93.67 91.11

PTC Therapeutics  (NAS:PTCT) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

PTC Therapeutics Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of PTC Therapeutics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

PTC Therapeutics Business Description

PTC Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Comparable Companies
NAS:ARVN NAS:FOLD NAS:FATE NAS:INSM NAS:CORT NAS:ABCL NAS:BEAM NAS:EQRX NAS:IOVA NAS:SAGE OCSE:NOVO B ASX:CSL NAS:REGN NAS:VRTX NAS:MRNA XKRX:207940 NAS:BNTX HKSE:02269 NAS:SGEN SZSE:300122
Traded in Other Exchanges
P91:Germany P91:Germany
Address
100 Corporate Court, South Plainfield, NJ, USA, 07080
Website
https://www.ptcbio.com
PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
Executives
Southwell David P director C/O INOTEK PHARMACEUTICALS CORPORATION 91 HARTWELL AVENUE LEXINGTON MA 02421
Jacobson Allan Steven director PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Peltz Stuart Walter director, officer: Chief Executive Officer PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Utter Christine Marie officer: SVP, Finance & CAO C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Boulding Mark Elliott officer: Exec. VP and CLO C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Hill Emily Luisa officer: Chief Financial Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Svoronos Dawn director C/O MEDIVATION, INC. 525 MARKET ST., 36TH FLOOR SAN FRANCISCO CA 94105
Pauwels Eric officer: Chief Business Officer 550 HILLS DRIVE BEDMINSTER NJ 07921
Klein Matthew B. officer: Chief Development Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Schmertzler Michael director 1300 VALLEY ROAD NEW CANAAN CT 06840
Souza Marcio officer: Chief Operating Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Almstead Neil Gregory officer: Chief Technical Ops Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Reeve Emma director C/O PAREXEL INTERNATIONAL CORPORATION 195 WEST STREET WALTHAM MA 02451
Steele Glenn Jr Md Phd director 250 TECHNOLOGY PARK LAKE MARY FL 32746-6232
Zeldis Jerome B director 8767 E. VIA DE VENTURA, SUITE 190 SCOTTSDALE AZ 85258

PTC Therapeutics Headlines

From GuruFocus

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By PRNewswire 12-02-2021

PTC Therapeutics Announces Launch of 8th Annual STRIVE™ Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community

By PRNewswire 01-18-2022

Results Show Long-Lasting and Holistic Improvements in Children with AADC Deficiency Treated with PTC-AADC Gene Therapy

By PRNewswire 09-29-2021

PTC Therapeutics to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference

By PRNewswire 01-03-2022

Waylivra™ Receives Innovative Drug Category Pricing to Treat Familial Chylomicronemia Syndrome in Brazil

By PRNewswire 01-04-2022

Oral Splicing Modifiers that Systemically Lower Huntington Disease Protein Discovered Through PTC Therapeutics' Innovative Splicing Platform

By PRNewswire 12-20-2021

PTC Therapeutics Announces Waylivra™ Approval in Brazil as First Treatment for Familial Chylomicronemia Syndrome

By PRNewswire 08-23-2021

PTC Therapeutics Announces Initiation of PIVOT-HD Phase 2 Clinical Trial to Evaluate PTC518 in Patients with Huntington's Disease

By PRNewswire 03-30-2022

FDA Grants Evrysdi® Priority Review Based on Results From Treating Pre-Symptomatic Infants with Spinal Muscular Atrophy

By PRNewswire 01-25-2022

STRIDE Data Show Translarna™ Delays Loss of Ambulation by More Than Five Years in Boys with Nonsense Mutation Duchenne Muscular Dystrophy

By PRNewswire 09-20-2021

Other Sources

Strength Seen in PTC Therapeutics (PTCT): Can Its 5.1% Jump Turn into More Strength?

By Zacks 2022-01-11

PTC Therapeutics (PTCT) Reports Q4 Loss, Tops Revenue Estimates

By Zacks 2022-02-22

PTC Therapeutics' (PTCT) PTC923 Gets Orphan Drug Tag in US & EU

By Zacks 2021-05-27

Is a Surprise Coming for PTC Therapeutics (PTCT) This Earnings Season?

By Zacks 2022-02-18

Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for

By Zacks 2020-10-22

$PTCT - PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q3 2020 Results - Earnings Call Transcript.…

By Seekingalpha 2020-10-30

PTC Therapeutics Gets First Milestone Payment for SMA Drug

By Zacks 2020-08-27

PTC Therapeutics (PTCT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

By Zacks 2021-07-22

$PTCT - PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q2 2021 Results - Earnings Call Transcript.…

By Seekingalpha 2021-07-29

$PTCT - PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q4 2021 Results - Earnings Call Transcript.…

By Seekingalpha 2022-02-23

$PTCT - PTC Therapeutics: Best Price-Positioned Biotech Developer Stock, As Seen By Market-Makers.…

By Seekingalpha 2021-01-23

PTC Therapeutics (PTCT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

By Zacks 2021-02-18

Earnings Preview: PTC Therapeutics (PTCT) Q3 Earnings Expected to Decline

By Zacks 2021-10-21

$PTCT - PTC Therapeutics, Inc (PTCT) CEO Stuart Peltz on Q4 2020 Results - Earnings Call Transcript.…

By Seekingalpha 2021-02-26

United Therapeutics (UTHR) Moves 3.1% Higher: Will This Strength Last?

By Zacks 2022-03-14

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)